Mallinckrodt PLC (MNK) Rating Lowered to Hold at Vetr Inc.
A number of other equities research analysts have also commented on the company. Mizuho restated a buy rating and set a $85.00 price objective on shares of Mallinckrodt PLC in a research report on Thursday, January 19th. Leerink Swann restated an outperform rating and set a $92.00 price objective on shares of Mallinckrodt PLC in a research report on Saturday, November 19th. Zacks Investment Research upgraded Mallinckrodt PLC from a sell rating to a buy rating and set a $64.00 price objective for the company in a research report on Tuesday, November 8th. BMO Capital Markets restated an outperform rating and set a $92.00 price objective on shares of Mallinckrodt PLC in a research report on Tuesday, November 29th. Finally, Oppenheimer Holdings, Inc. restated an outperform rating on shares of Mallinckrodt PLC in a research report on Tuesday, December 20th. Five equities research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company’s stock. The company presently has a consensus rating of Buy and an average price target of $79.66.
Shares of Mallinckrodt PLC (NYSE:MNK) opened at 52.50 on Monday. Mallinckrodt PLC has a 52-week low of $42.67 and a 52-week high of $85.83. The stock’s 50 day moving average is $49.66 and its 200-day moving average is $62.31. The firm has a market cap of $5.50 billion, a P/E ratio of 20.37 and a beta of 1.48.
Mallinckrodt PLC (NYSE:MNK) last announced its quarterly earnings data on Tuesday, February 7th. The company reported $1.91 EPS for the quarter, topping the Zacks’ consensus estimate of $1.82 by $0.09. Mallinckrodt PLC had a return on equity of 17.34% and a net margin of 7.75%. The firm earned $829.90 million during the quarter, compared to analyst estimates of $827.12 million. During the same period last year, the company posted $1.97 EPS. The business’s quarterly revenue was down 8.9% compared to the same quarter last year. Equities analysts anticipate that Mallinckrodt PLC will post $7.56 earnings per share for the current fiscal year.
“Mallinckrodt PLC (MNK) Rating Lowered to Hold at Vetr Inc.” was first published by Watch List News and is the sole property of of Watch List News. If you are viewing this piece on another publication, it was illegally stolen and reposted in violation of U.S. and international copyright law. The correct version of this piece can be viewed at http://www.watchlistnews.com/mallinckrodt-plc-mnk-rating-lowered-to-hold-at-vetr-inc/1121788.html.
In related news, insider Mark Trudeau bought 1,000 shares of Mallinckrodt PLC stock in a transaction that occurred on Tuesday, February 14th. The stock was purchased at an average cost of $50.47 per share, for a total transaction of $50,470.00. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 0.53% of the stock is currently owned by insiders.
A number of large investors have recently bought and sold shares of the company. Lebenthal Asset Management LLC raised its stake in Mallinckrodt PLC by 1.9% in the fourth quarter. Lebenthal Asset Management LLC now owns 36,398 shares of the company’s stock valued at $1,814,000 after buying an additional 669 shares during the period. Boothbay Fund Management LLC bought a new stake in Mallinckrodt PLC during the fourth quarter valued at $257,000. Cigna Investments Inc. New bought a new stake in Mallinckrodt PLC during the fourth quarter valued at $1,110,000. Ladenburg Thalmann Financial Services Inc. raised its stake in Mallinckrodt PLC by 2.8% in the fourth quarter. Ladenburg Thalmann Financial Services Inc. now owns 2,834 shares of the company’s stock valued at $143,000 after buying an additional 78 shares during the period. Finally, AQR Capital Management LLC raised its stake in Mallinckrodt PLC by 76.7% in the fourth quarter. AQR Capital Management LLC now owns 3,232,782 shares of the company’s stock valued at $161,058,000 after buying an additional 1,403,738 shares during the period. Hedge funds and other institutional investors own 88.79% of the company’s stock.
Mallinckrodt PLC Company Profile
Mallinckrodt public limited company develops, manufactures, markets and distributes branded and generic specialty pharmaceutical products and therapies. The Company focuses on various therapeutic areas, such as autoimmune and rare disease specialty areas, including neurology, rheumatology, nephrology, ophthalmology and pulmonology; immunotherapy and neonatal critical care respiratory therapies; analgesics and hemostasis products, and central nervous system drugs.
To view Vetr’s full report, visit Vetr’s official website.
Receive News & Ratings for Mallinckrodt PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mallinckrodt PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.